Detalhe da pesquisa
1.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Gastroenterology
; 158(8): 2123-2138.e8, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32044319
2.
Healthcare Providers Underestimate Patients' Glucocorticoid Use in Crohn's Disease.
Dig Dis Sci
; 64(5): 1142-1149, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30659472
3.
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Lancet
; 390(10114): 2779-2789, 2017 12 23.
Artigo
Inglês
| MEDLINE | ID: mdl-29096949
4.
Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial.
Gastrointest Endosc
; 83(1): 188-97.e1-3, 2016 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-26234693
5.
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
Gastroenterology
; 146(4): 941-9, 2014 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-24361468
6.
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
Gastroenterology
; 146(1): 110-118.e3, 2014 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-24067881
7.
Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
Clin Gastroenterol Hepatol
; 13(5): 940-8.e3, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25245624
8.
Adalimumab induces deep remission in patients with Crohn's disease.
Clin Gastroenterol Hepatol
; 12(3): 414-22.e5, 2014 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-23856361
9.
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
Am J Gastroenterol
; 109(11): 1771-80, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-25155227
10.
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Gastroenterology
; 142(2): 257-65.e1-3, 2012 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-22062358
11.
Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
Am J Cardiovasc Drugs
; 9(2): 69-79, 2009.
Artigo
Inglês
| MEDLINE | ID: mdl-19331435
12.
Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.
Inflamm Bowel Dis
; 24(5): 932-942, 2018 04 23.
Artigo
Inglês
| MEDLINE | ID: mdl-29668919
13.
Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial.
Intest Res
; 15(3): 395-401, 2017 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-28670237
14.
Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn's Disease.
Inflamm Bowel Dis
; 23(6): 967-975, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28301428
15.
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.
J Crohns Colitis
; 11(11): 1317-1325, 2017 Oct 27.
Artigo
Inglês
| MEDLINE | ID: mdl-28981846
16.
Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease.
Inflamm Bowel Dis
; 23(3): 453-460, 2017 03.
Artigo
Inglês
| MEDLINE | ID: mdl-28129288
17.
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease.
Intest Res
; 14(2): 152-63, 2016 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-27175116
18.
Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.
Inflamm Bowel Dis
; 22(4): 886-93, 2016 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-26950307
19.
Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
Inflamm Bowel Dis
; 21(4): 783-92, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25723614
20.
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
J Gastroenterol
; 49(2): 283-94, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24363029